| pubmed-article:2538330 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2538330 | lifeskim:mentions | umls-concept:C0007600 | lld:lifeskim |
| pubmed-article:2538330 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:2538330 | lifeskim:mentions | umls-concept:C0042395 | lld:lifeskim |
| pubmed-article:2538330 | lifeskim:mentions | umls-concept:C0597357 | lld:lifeskim |
| pubmed-article:2538330 | lifeskim:mentions | umls-concept:C0237753 | lld:lifeskim |
| pubmed-article:2538330 | lifeskim:mentions | umls-concept:C1521991 | lld:lifeskim |
| pubmed-article:2538330 | lifeskim:mentions | umls-concept:C0005456 | lld:lifeskim |
| pubmed-article:2538330 | lifeskim:mentions | umls-concept:C1880022 | lld:lifeskim |
| pubmed-article:2538330 | lifeskim:mentions | umls-concept:C0971125 | lld:lifeskim |
| pubmed-article:2538330 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:2538330 | pubmed:dateCreated | 1989-5-11 | lld:pubmed |
| pubmed-article:2538330 | pubmed:abstractText | Using mono[125I]iodinated vasoactive intestinal peptide (125I-VIP), a very high number of specific binding sites for VIP were identified at the surface of the human melanoma cell line IGR39. The Scatchard analysis of competitive displacement experiments between native VIP and 125I-VIP was consistent with the existence of two classes of VIP-binding sites. IGR39 cells possess 0.54 x 10(6) high-affinity sites with a dissociation constant (Kd) of 0.66 nM and 1.3 x 10(6) sites of moderate affinity with a Kd of 4.7 nM. Pharmacological studies indicated that the order of potency in inhibiting 125I-VIP binding of the VIP/secretin family peptides was VIP much greater than peptide histidine methioninamide greater than human growth-hormone-releasing factor(1-44) greater than secretin. Glucagon has no effect on the binding of the labelled peptide. By means of photoaffinity labelling a polypeptide of Mr 63,000 was characterized. The labelling of this species was completely abolished by native VIP. The order of potency of VIP-related peptides in inhibiting 125I-VIP cross-linking to its receptor was the same as in the competition experiments. The glycoprotein nature of the VIP-binding sites of IGR39 cells has been investigated by affinity chromatography on wheat-germ-agglutinin-Sepharose. | lld:pubmed |
| pubmed-article:2538330 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2538330 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2538330 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2538330 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2538330 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2538330 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2538330 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2538330 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:2538330 | pubmed:issn | 0014-2956 | lld:pubmed |
| pubmed-article:2538330 | pubmed:author | pubmed-author:MarvaldiJJ | lld:pubmed |
| pubmed-article:2538330 | pubmed:author | pubmed-author:MartinJ MJM | lld:pubmed |
| pubmed-article:2538330 | pubmed:author | pubmed-author:PichonJJ | lld:pubmed |
| pubmed-article:2538330 | pubmed:author | pubmed-author:LuisJJ | lld:pubmed |
| pubmed-article:2538330 | pubmed:author | pubmed-author:ReynierMM | lld:pubmed |
| pubmed-article:2538330 | pubmed:author | pubmed-author:el BattariAA | lld:pubmed |
| pubmed-article:2538330 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2538330 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:2538330 | pubmed:volume | 180 | lld:pubmed |
| pubmed-article:2538330 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2538330 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2538330 | pubmed:pagination | 429-33 | lld:pubmed |
| pubmed-article:2538330 | pubmed:dateRevised | 2007-7-23 | lld:pubmed |
| pubmed-article:2538330 | pubmed:meshHeading | pubmed-meshheading:2538330-... | lld:pubmed |
| pubmed-article:2538330 | pubmed:meshHeading | pubmed-meshheading:2538330-... | lld:pubmed |
| pubmed-article:2538330 | pubmed:meshHeading | pubmed-meshheading:2538330-... | lld:pubmed |
| pubmed-article:2538330 | pubmed:meshHeading | pubmed-meshheading:2538330-... | lld:pubmed |
| pubmed-article:2538330 | pubmed:meshHeading | pubmed-meshheading:2538330-... | lld:pubmed |
| pubmed-article:2538330 | pubmed:meshHeading | pubmed-meshheading:2538330-... | lld:pubmed |
| pubmed-article:2538330 | pubmed:meshHeading | pubmed-meshheading:2538330-... | lld:pubmed |
| pubmed-article:2538330 | pubmed:meshHeading | pubmed-meshheading:2538330-... | lld:pubmed |
| pubmed-article:2538330 | pubmed:meshHeading | pubmed-meshheading:2538330-... | lld:pubmed |
| pubmed-article:2538330 | pubmed:meshHeading | pubmed-meshheading:2538330-... | lld:pubmed |
| pubmed-article:2538330 | pubmed:meshHeading | pubmed-meshheading:2538330-... | lld:pubmed |
| pubmed-article:2538330 | pubmed:year | 1989 | lld:pubmed |
| pubmed-article:2538330 | pubmed:articleTitle | A human melanoma-derived cell line (IGR39) with a very high number of vasoactive-intestinal-peptide (VIP) receptors. 1. Molecular characterization of the binding site. | lld:pubmed |
| pubmed-article:2538330 | pubmed:affiliation | Institut de Chimie Biologique, Unité Associée au Centre National de la Recherche Scientifique no. 202, Université de Provence, Marseille, France. | lld:pubmed |
| pubmed-article:2538330 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2538330 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2538330 | lld:pubmed |
